News & Events

News Archive

11 December 2017Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

13 November 2017Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate

31 October 2017Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

04 October 2017Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

18 September 2017Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases

07 July 2017Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK

03 July 2017Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline

05 June 2017Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting

01 June 2017Immunocore Highlights IMCgp100 clinical data in Uveal Melanoma at ASCO 2017 Annual Meeting

12 May 2017Abbas Hussain Joins the Board of Immunocore as Non-Executive Director

1
2
→

News archive